11:41 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Blisibimod: Ph III CHABLIS-SC1 data

Top-line data from the double-blind, international Phase III CHABLIS-SC1 trial in about 442 patients with SLE despite ongoing stable corticosteroid therapy showed that once-weekly subcutaneous blisibimod missed the primary endpoint of a greater proportion of...
07:00 , Oct 3, 2016 |  BioCentury  |  Finance

ASH and others

Cancer and hematology companies are likely to garner the most headlines in 4Q16 thanks to ESMO in October and ASH in December, but some investors also are branching out to events that typically receive less...
07:00 , Jul 25, 2016 |  BC Week In Review  |  Clinical News

Blisibimod: Interim Phase II data

Interim data from the double-blind, international Phase II BRIGHT-SC trial in 57 patients with biopsy-proven IgA nephropathy showed that subcutaneous blisibimod missed the primary endpoint of a greater number of patients who achieved a partial...
08:00 , Nov 16, 2015 |  BioCentury  |  Product Development

On SLE's trail

AstraZeneca plc's MedImmune LLC unit is following a clinical development trail for lupus candidate anifrolumab first blazed by Benlysta belimumab. The company hopes that its track record of successful mid-stage trials in the indication have...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Anthera, Zenyaku deal

Zenyaku terminated a December 2014 deal with Anthera granting Zenyaku exclusive rights to develop and commercialize blisibimod in Japan and an option to license rights to blisibimod in undisclosed additional Asian countries. Anthera will regain...
07:00 , Jun 22, 2015 |  BC Week In Review  |  Clinical News

Blisibimod: Completed Phase III enrollment

Anthera completed enrollment of 400 patients with active SLE despite ongoing stable corticosteroid therapy in the double-blind, placebo-controlled, international Phase III CHABLIS-SC1 trial evaluating 200 mg subcutaneous blisibimod once weekly for 52 weeks. Anthera has...
08:00 , Mar 2, 2015 |  BC Week In Review  |  Clinical News

Blisibimod: Phase III ongoing

Anthera said an independent DSMB recommended continuation of the double-blind, placebo-controlled, international Phase III CHABLIS-SC1 trial of blisibimod based on an interim futility analysis of the SRI-6 response at 24 weeks. CHABLIS-SC1 is evaluating once-weekly...
03:06 , Oct 3, 2014 |  BC Extra  |  Clinical News

Lilly halts tabalumab for lupus

Eli Lilly and Co. (NYSE:LLY) said it will discontinue development of tabalumab to treat systemic lupus erythematosus (SLE) because it failed to show sufficient efficacy in two Phase III trials. The pharma said its decision...
07:00 , Apr 7, 2014 |  BioCentury  |  Finance

1Q Stock Wrap-Up: Small but mighty

Despite a correction at the end of March, all biotech market cap segments finished the first quarter in positive territory. Microcaps set the pace with a 10% gain, while large caps added 7% and were...
07:00 , Jul 1, 2013 |  BC Week In Review  |  Clinical News

Blisibimod: Phase II started

Anthera began the double-blind, placebo-controlled, Asian Phase II BRIGHT-SC trial to evaluate blisibimod in >=48 patients. Anthera plans to conduct an interim analysis after patients have completed 8 weeks of treatment. The company plans to...